• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Recalcitrant epidermolysis bullosa acquisita treated with upadacitinib as a bridge to rituximab.

作者信息

Rasul Taha, Concilla Anthony, Militello Michelle, Torres Paola, Stepien Angelia

机构信息

HCA Florida Orange Park Hospital, Orange Park, Florida.

出版信息

JAAD Case Rep. 2025 Jun 25;63:34-37. doi: 10.1016/j.jdcr.2025.06.022. eCollection 2025 Sep.

DOI:10.1016/j.jdcr.2025.06.022
PMID:40787064
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12328672/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/020d/12328672/992cfc87c961/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/020d/12328672/5adc988df143/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/020d/12328672/992cfc87c961/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/020d/12328672/5adc988df143/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/020d/12328672/992cfc87c961/gr2.jpg

相似文献

1
Recalcitrant epidermolysis bullosa acquisita treated with upadacitinib as a bridge to rituximab.用乌帕替尼作为通向利妥昔单抗的桥梁治疗难治性获得性大疱性表皮松解症。
JAAD Case Rep. 2025 Jun 25;63:34-37. doi: 10.1016/j.jdcr.2025.06.022. eCollection 2025 Sep.
2
A Case Report of the Use of Rituximab and the Epidermolysis Bullosa Disease Activity Scoring Index (EBDASI) in a Patient with Epidermolysis Bullosa Acquisita with Extensive Esophageal Involvement.利妥昔单抗及大疱性表皮松解症疾病活动评分指数（EBDASI）用于广泛食管受累的获得性大疱性表皮松解症患者的病例报告
Acta Dermatovenerol Croat. 2018 Dec;26(4):325-328.
3
A case of recalcitrant epidermolysis bullosa acquisita responsive to rituximab therapy.1例对利妥昔单抗治疗有效的顽固性获得性大疱性表皮松解症病例。
Pediatr Dermatol. 2014 Mar-Apr;31(2):241-4. doi: 10.1111/pde.12006. Epub 2012 Oct 29.
4
Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies).重症机械性大疱性获得性大疱性表皮松解症对免疫吸附联合利妥昔单抗（抗CD20单克隆抗体）治疗的临床反应
Arch Dermatol. 2007 Feb;143(2):192-8. doi: 10.1001/archderm.143.2.192.
5
Case Report: Diagnostic and Therapeutic Challenges in Severe Mechanobullous Epidermolysis Bullosa Acquisita.病例报告：严重机械性大疱性表皮松解症获得性的诊断和治疗挑战。
Front Immunol. 2022 Apr 7;13:883967. doi: 10.3389/fimmu.2022.883967. eCollection 2022.
6
Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients.获得性大疱性表皮松解症患者的临床和免疫病理学特征及治疗结局的荟萃分析。
Orphanet J Rare Dis. 2018 Sep 4;13(1):153. doi: 10.1186/s13023-018-0896-1.
7
The use of rituximab in treatment of epidermolysis bullosa acquisita: Three new cases and a review of the literature.应用利妥昔单抗治疗获得性大疱性表皮松解症：三例新病例及文献复习。
Dermatol Ther. 2018 Nov;31(6):e12726. doi: 10.1111/dth.12726. Epub 2018 Oct 3.
8
Efficacy of rituximab in the treatment of epidermolysis bullosa acquisita.利妥昔单抗治疗获得性大疱性表皮松解症的疗效。
Clin Exp Dermatol. 2024 Dec 23;50(1):97-103. doi: 10.1093/ced/llae283.
9
Epidermolysis bullosa acquisita and associated symptomatic esophageal webs.获得性大疱性表皮松解症及相关症状性食管蹼
Arch Dermatol. 1991 Mar;127(3):373-7.
10
Epidermolysis bullosa acquisita.获得性大疱性表皮松解症。
J Eur Acad Dermatol Venereol. 2013 Oct;27(10):1204-13. doi: 10.1111/jdv.12096. Epub 2013 Feb 1.

本文引用的文献

1
Efficacy of rituximab in the treatment of epidermolysis bullosa acquisita.利妥昔单抗治疗获得性大疱性表皮松解症的疗效。
Clin Exp Dermatol. 2024 Dec 23;50(1):97-103. doi: 10.1093/ced/llae283.
2
Treatment of Epidermolysis bullosa acquisita with dupilumab.用度普利尤单抗治疗获得性大疱性表皮松解症。
J Dtsch Dermatol Ges. 2024 Oct;22(10):1417-1419. doi: 10.1111/ddg.15478. Epub 2024 Aug 2.
3
Upadacitinib for the management of bullous pemphigoid coexisting with psoriasis vulgaris: a case report and literature review.乌帕替尼治疗寻常型银屑病合并大疱性类天疱疮 1 例报告及文献复习
J Dermatolog Treat. 2024 Dec;35(1):2302394. doi: 10.1080/09546634.2024.2302394. Epub 2024 Jan 23.
4
Janus kinase inhibitors in autoimmune bullous diseases.自身免疫性大疱性疾病的 Janus 激酶抑制剂。
Front Immunol. 2023 Jul 10;14:1220887. doi: 10.3389/fimmu.2023.1220887. eCollection 2023.
5
A literature review on Janus kinase (JAK) inhibitors for the treatment of immunobullous disorders.关于 Janus 激酶（JAK）抑制剂治疗免疫性大疱性疾病的文献综述。
Int Immunopharmacol. 2022 Sep;110:108923. doi: 10.1016/j.intimp.2022.108923. Epub 2022 Jun 16.
6
The safety of JAK-1 inhibitors.JAK-1 抑制剂的安全性。
Rheumatology (Oxford). 2021 May 5;60(Suppl 2):ii24-ii30. doi: 10.1093/rheumatology/keaa895.
7
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3.美国风湿病学会在 COVID-19 大流行期间成人患者风湿病管理指南：第 3 版。
Arthritis Rheumatol. 2021 Feb;73(2):e1-e12. doi: 10.1002/art.41596. Epub 2020 Dec 5.
8
Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients.获得性大疱性表皮松解症患者的临床和免疫病理学特征及治疗结局的荟萃分析。
Orphanet J Rare Dis. 2018 Sep 4;13(1):153. doi: 10.1186/s13023-018-0896-1.
9
International Bullous Diseases Group: consensus on diagnostic criteria for epidermolysis bullosa acquisita.国际大疱性疾病组织：获得性大疱性表皮松解症的诊断标准共识。
Br J Dermatol. 2018 Jul;179(1):30-41. doi: 10.1111/bjd.16138. Epub 2018 May 8.
10
Epidermolysis bullosa acquisita.获得性大疱性表皮松解症。
Clin Dermatol. 2012 Jan-Feb;30(1):60-9. doi: 10.1016/j.clindermatol.2011.03.011.